Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

805228

registered interest
date	12/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether his Department plans to publish a strategy to eliminate hepatitis C.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	118900
answer	answer is ministerial correction date of answer 20/12/2017 answer text <p>The Government is committed to meeting the World Health Organization target of eliminating hepatitis C by 2030 but there are no plans at this time to publish a strategy to eliminate hepatitis C. A variety of initiatives are underway in England to improve awareness and case finding, re-engagement and linkage to care, especially in drug services, primary care, prisons and accident and emergency centres. In addition, NHS England is funding access to new hepatitis C treatments in accordance with guidance from the National Institute for Health and Care Excellence.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/12/2017 17:24:50 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

805229

registered interest
date	12/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to NHS England's press release of 28 July 2016 entitled World Hepatitis Day: a chance to reflect on achievements to date and redouble efforts, what discussions his Department has had with NHS England on developing more innovative, longer-term proposals for the treatment of hepatitis C.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	118901
answer	answer is ministerial correction date of answer 20/12/2017 answer text <p>Following a procurement process that concluded in September 2017, NHS England has secured further improvements in pricing of hepatitis C treatments, including through an innovative ‘pay per cure’ approach. NHS England’s detailed work to design an innovative, longer-term approach to hepatitis C treatment procurement has continued and it is anticipated that this will be shared with suppliers early in 2018.</p><p> </p><p>NHS England spent in excess of £200 million on direct acting antivirals for hepatitis C in 2016-17 and is funding access to new hepatitis C treatments in accordance with guidance from the National Institute for Health and Care Excellence, apportioned to local Operational Delivery Networks based on estimated local health needs.</p><p> </p><p>NHS England is planning a sustainable roll out of treatment which will complete the treatment of 71,000 individuals between 2015/16 and 2020/21.</p><p> </p><p>Commercial and contractual activity undertaken by NHS England is already securing reduced prices to allow expanded treatment rates within available resources.</p><p> </p><p>Various initiatives are underway in England to improve awareness and case finding, re-engagement and linkage to care, especially in drug services, primary care, prisons and accident and emergency centres recognising the challenges inherent in a pathway where there are multiple commissioners and providers and budgetary constraints.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/12/2017 17:27:51 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

784744

registered interest
date	06/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to improve the detection of hepatitis B and hepatitis C.
tabling member printed	Baroness Randerson
uin	HL2962
answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>The National Institute for Health and Clinical Excellence (NICE) guidelines are available to help raise awareness of, and testing for, hepatitis B and C infection in people at increased risk of infection. Screening for hepatitis B and C is recommended in groups who are at increased risk of infection so that diagnosed individuals can be referred for specialist care and management. NICE has also produced best practice guidance on hepatitis B antenatal screening and the new-born immunisation programme.</p><p> </p><p>NHS England commissions the infectious diseases in pregnancy screening programme, including the screening for hepatitis B, as of part of the maternity pathway. In addition and as part of health services commissioned for those in detained settings, NHS England is rolling out an ambitious Opt-Out Blood Borne Viruses (BBV) testing programme. The key aim is to improve uptake rates for hepatitis B and hepatitis C testing by the introduction of good practice for ‘meaningful offer’ of BBV testing across the adult prison estate by end of 2017-18.</p> answering member printed Lord O'Shaughnessy question first answered 20/11/2017 12:17:03 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4230 label Biography information for Baroness Randerson

776804

registered interest
date	24/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government further to the Written Answer by Lord O'Shaughnessy on 17 July (HL530), what support they are giving to Operational Delivery Networks which did not achieve their run rates in the period 2016–17 to meet those targets in the future.
tabling member printed	Baroness Randerson
uin	HL2468
answer	answer is ministerial correction date of answer 07/11/2017 answer text <p>In 2016-17, Operational Delivery Networks achieved 94% of the planned treatment run rate of 10,000 patients, with all but two treating over 90% of their run rate. NHS England has a Commissioning for Quality and Innovation scheme in place for hepatitis C virus (HCV), which provides a substantial opportunity for hospitals to earn additional income available to invest in their contribution to the sustainable rollout of HCV treatments. NHS England also invested £1 million in fibroscanning equipment to identify patients at the highest unmet clinical need. Clinical and commissioning support is provided at regional and national level to share best practice.</p> answering member printed Lord O'Shaughnessy question first answered 07/11/2017 15:48:47 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4230 label Biography information for Baroness Randerson

769701

registered interest
date	12/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to eliminate Hepatitis C.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	107488
answer	answer is ministerial correction date of answer 19/10/2017 answer text <p>The United Kingdom government is a signatory to the World Health Assembly resolution and World Health Organization (WHO) goal of eliminating hepatitis C as a major public health threat by 2030.</p><p> </p><p>Progress towards achieving the WHO elimination goal is summarised in this year’s Public Health England’s (PHE) report “Hepatitis C in the UK”:</p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/632465/HCV_in_the_uk_report_2017.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/632465/HCV_in_the_uk_report_2017.pdf</a></p><p>This showed that better access to improved treatment has led to the first fall in deaths from severe hepatitis C related liver disease in a decade and that the UK is on target for the WHO interim goal to reduce hepatitis C mortality by 10% by 2020.</p><p> </p><p>For England a sustainable rollout of access to new direct acting antivirals for treating chronic hepatitis C is underway with investment of in excess of £200 million per year. The current financial year (2017/18) is the third year of hepatitis C treatment ramp-up and the plan is to treat 12,500 individuals.</p><p> </p><p>An estimated 160,000 persons are believed to have hepatitis C in England. Further modelling work is being undertaken by PHE to update estimates of the impact of treatment roll out on prevalence of hepatitis C and hepatitis C-associated advanced liver disease. Previous PHE modelling of the scale up of treatment indicates that a “rapid complete coverage” scenario of treating 20,000 or more individuals per year and up to 50% of those infected each year would result in end-stage liver disease / hepatocellular cancer being halved within 10 years.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 107489 question first answered 19/10/2017 15:17:27 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

769702

registered interest
date	12/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the number of people who require treatment each year to meet the UK's commitment to eliminate Hepatitis C as a public health concern by 2030.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	107489
answer	answer is ministerial correction date of answer 19/10/2017 answer text <p>The United Kingdom government is a signatory to the World Health Assembly resolution and World Health Organization (WHO) goal of eliminating hepatitis C as a major public health threat by 2030.</p><p> </p><p>Progress towards achieving the WHO elimination goal is summarised in this year’s Public Health England’s (PHE) report “Hepatitis C in the UK”:</p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/632465/HCV_in_the_uk_report_2017.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/632465/HCV_in_the_uk_report_2017.pdf</a></p><p>This showed that better access to improved treatment has led to the first fall in deaths from severe hepatitis C related liver disease in a decade and that the UK is on target for the WHO interim goal to reduce hepatitis C mortality by 10% by 2020.</p><p> </p><p>For England a sustainable rollout of access to new direct acting antivirals for treating chronic hepatitis C is underway with investment of in excess of £200 million per year. The current financial year (2017/18) is the third year of hepatitis C treatment ramp-up and the plan is to treat 12,500 individuals.</p><p> </p><p>An estimated 160,000 persons are believed to have hepatitis C in England. Further modelling work is being undertaken by PHE to update estimates of the impact of treatment roll out on prevalence of hepatitis C and hepatitis C-associated advanced liver disease. Previous PHE modelling of the scale up of treatment indicates that a “rapid complete coverage” scenario of treating 20,000 or more individuals per year and up to 50% of those infected each year would result in end-stage liver disease / hepatocellular cancer being halved within 10 years.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 107488 question first answered 19/10/2017 15:17:27 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

759586

registered interest
date	12/09/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they have established the cross-agency expert group on viral hepatitis to provide strategic direction and advice around hepatitis C and other viral hepatitis, as announced in March.
tabling member printed	Baroness Randerson
uin	HL1556
answer	answer is ministerial correction date of answer 20/09/2017 answer text <p>With the support of the Department and the Chief Medical Officer, Public Health England (PHE) has established a national cross-agency expert group, the National Strategic Group on Viral Hepatitis, to provide strategic direction and advice around all types of viral hepatitis, including hepatitis C. It will provide advice to PHE, the Department, NHS England and to the wider health system. The new group is committed to working towards the World Health Organization goal to eliminate viral hepatitis as a major public health threat and brings together partner organisations to improve health services, minimise the number of new infections and reduce the health consequences of viral hepatitis for people in England. A priority is addressing the cross-system operational barriers in case finding and treatment capacity.</p> answering member printed Lord O'Shaughnessy question first answered 20/09/2017 13:22:49 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	4230 label Biography information for Baroness Randerson

722235

registered interest
date	18/04/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, for what reason the list price for (a) telaprevir, (b) boceprevir, (c) simeprevir, (d) sofosbuvir and (e) ledipasvir-sofosbuvir hepatitis C treatment is higher in the NHS than in other countries.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	71107
answer	answer is ministerial correction date of answer 26/04/2017 answer text <p>These hepatitis C medicines were all granted new active substance marketing authorisations by the licensing authorities. Under the terms of the 2014 Pharmaceutical Price Regulation Scheme new active substances can be priced at the discretion of companies on entering the market. However, the National Health Service is involved in commercial activities with the relevant pharmaceutical companies to secure best value in hepatitis C treatment. Discounts secured mean that the actual prices paid for medicines often do not reflect list prices. Confidential discounts occur in other countries too, which makes it impossible to undertake price comparisons with other countries.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 26/04/2017 09:46:30 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1533 label Biography information for Dame Diana Johnson

715517

registered interest
date	30/03/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord O’Shaughnessy on 22 March (HL5975), what steps they are taking to ensure that more precise figures on the number of people with undiagnosed Hepatitis C are made available.
tabling member printed	Baroness Randerson
uin	HL6478
answer	answer is ministerial correction date of answer 06/04/2017 answer text <p>Most recent estimates suggest that around 160,000 people in England are living with chronic hepatitis C (HCV) infection. Published figures of the number who remain undiagnosed are not available although surveillance data and modelling are used to generate estimates for healthcare planning assumptions.</p><p>An estimate of the proportion of people who inject drugs who are diagnosed can be obtained from the Public Health England survey entitled <em>Data tables of the Unlinked Anonymous Monitoring Survey of HIV and Hepatitis in People Who Inject Drugs</em>. A copy of this survey is attached.</p><p>In this survey, only around one half of people injecting psychoactive drugs sampled are aware of their HCV antibody positive status (53% in 2015), and this figure has remained relatively stable at this level (averaging 52%) over the past decade.</p> answering member printed Lord O'Shaughnessy question first answered 06/04/2017 10:59:16 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name Data tables of the Unlinked Anonymous Monitoring Survey of HIV and Hepatitis in People Who Inject Drugs.pdf title PHE Survey - Data Tables
tabling member	4230 label Biography information for Baroness Randerson

715684

registered interest
date	30/03/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the adequacy of treatment provision for people diagnosed with (a) hepatitis B and (b) hepatitis C.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	70166
answer	answer is ministerial correction date of answer 18/04/2017 answer text <p>The responsibility for the provision of care services for people with diagnosed hepatitis B and C is shared between commissioners. NHS England is the responsible commissioner for drug treatments excluded from national tariff for these conditions. NHS England commissions hepatitis B and C treatments in accordance with National Institute for Health and Care Excellence (NICE) technology appraisal guidance.</p><p> </p><p>In the case of hepatitis C, the National Health Service is on track to treat 10,000 individuals with diagnosed hepatitis C which is in line with estimates of uptake published in a costing template published alongside NICE guidance.</p><p> </p><p>Treatments which are not subject to such guidance are considered through NHS England’s policy development process which assesses the evidence of clinical and cost effectiveness and undertakes a relative prioritisation of investment decisions.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 18/04/2017 13:41:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	308 label Biography information for Mr Jim Cunningham